Tirnovetmab Biosimilar – Anti-IL31 (Canine) mAb – Research Grade

Description of Tirnovetmab Biosimilar - Anti-IL31 (Canine) mAb - Research Grade

Tirnovetmab Biosimilar: A Novel Anti-IL31 Antibody for Canine Therapeutics Introduction

Tirnovetmab Biosimilar is a monoclonal antibody (mAb) that specifically targets interleukin-31 (IL-31), a cytokine involved in the pathogenesis of various inflammatory and allergic diseases in dogs. This research grade antibody is a biosimilar of the commercially available drug, Lokivetmab, and has shown promising results in preclinical studies for the treatment of atopic dermatitis (AD) and other pruritic conditions in canines.

Structure of Tirnovetmab Biosimilar

Tirnovetmab Biosimilar is a recombinant, fully human IgG2 mAb with a molecular weight of approximately 150 kDa. It is produced using Chinese hamster ovary (CHO) cells and has a similar structure to Lokivetmab, with minor differences in glycosylation patterns. The antibody is composed of two heavy chains and two light chains, with each chain containing variable (V) and constant (C) regions. The V regions are responsible for binding to IL-31, while the C regions determine the antibody’s effector functions.

Mechanism of Action

IL-31 is a pro-inflammatory cytokine that is primarily produced by activated T cells and has been implicated in the development of pruritus (itching) in dogs. Tirnovetmab Biosimilar binds to IL-31 with high specificity and affinity, preventing it from interacting with its receptor on the surface of target cells. This inhibits the downstream signaling pathways that lead to the release of inflammatory mediators and ultimately reduces pruritus.

Applications of Tirnovetmab Biosimilar

Tirnovetmab Biosimilar has shown promising results in preclinical studies for the treatment of AD and other pruritic conditions in canines. AD is a common skin disease in dogs, characterized by intense itching, skin lesions, and secondary infections. It is a chronic and relapsing condition that significantly impacts the quality of life of affected dogs. Other pruritic conditions in canines include flea allergy dermatitis, food allergy, and contact dermatitis, which can also be effectively treated with Tirnovetmab Biosimilar.

Advantages of Tirnovetmab Biosimilar

Tirnovetmab Biosimilar has several advantages over other anti-IL-31 therapies currently available for dogs. As a biosimilar of Lokivetmab, it has a similar efficacy and safety profile, but at a lower cost. Being a fully human mAb, it has a lower risk of immunogenicity compared to other biologic drugs. Additionally, Tirnovetmab Biosimilar has a longer half-life, allowing for less frequent dosing and improved compliance.

Conclusion

Tirnovetmab Biosimilar is a novel anti-IL-31 mAb that has shown promising results in preclinical studies for the treatment of pruritic conditions in canines. Its unique structure and mechanism of action make it a highly specific and effective therapy for targeting IL-31, a key cytokine involved in the pathogenesis of pruritus. With its potential to improve the quality of life of dogs suffering from AD and other pruritic conditions, Tirnovetmab Biosimilar is a promising addition to the arsenal of therapies available for canine therapeutics.

SDS-PAGE for Tirnovetmab Biosimilar - Anti-IL31 (Canine) mAb

Tirnovetmab Biosimilar - Anti-IL31 (Canine) mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.